Back to search

Article

Microtubule targeting agents influence the clinical benefit of immune response in early breast cancer

2024-03-12

Abstract excerpt

<h4>PURPOSE</h4> Immune response to tumors is associated with clinical benefits in breast cancer. Preclinically, disruption of microtubule dynamics affect the functionality of immune cells. We investigate the impact of microtubule targeting agents (MTA) on the clinical benefit of immune response in early breast cancer. <h4>METHODS</h4> We used the gene expression dataset associated with the randomized FinHER adjuv...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5695efa0-fbe2-5ed6-9788-ebf525c27ad6
DOI
10.1101/2024.03.09.24304017
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Microtubule targeting agents influence the clinical benefit of immune response in early breast cancerDOI 10.1101/2024.03.09.24304017
TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanismsSemantic proximity
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer.Semantic proximity
Predicting Immunotherapy Response Through Chemotherapy-Induced Tumor Microenvironment RemodelingSemantic proximity
The MHCII Immune Activation Score predicts risk of recurrence and benefit of taxanes in Basal-like and HER2-enriched breast cancerSemantic proximity
A phase Ib trial evaluating the safety, efficacy, and immunologic effects of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancerSemantic proximity
Markers predicting clinical benefit in breast cancer from microtubule-targeting agentsSemantic proximity
Peripheral blood gene expression signatures of systemic immunity predict tumor microenvironment biology and therapeutic response in breast cancerSemantic proximity
Characteristics and Developmental Trajectory of Clinical Trials Focused on Tumor-Infiltrating Lymphocytes for Cancer TreatmentSemantic proximity
RFTN1: an potential inhibitor of the immunity system in TME of breast cancer improving the tumor immune escapeSemantic proximity
Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled AnalysisSemantic proximity
easier: interpretable predictions of antitumor immune response from bulk RNA-seq dataSemantic proximity
Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab TrialSemantic proximity
Select a neighboring publication to make it the new centre.